#News for #Investors and #Media: The US FDA has approved a new presentation of one of our vaccines. Learn more: https://gsk.to/44T7RWL
About us
We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://gsk.to/socialmedia
- Website
-
http://www.gsk.com
External link for GSK
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- London, England
- Type
- Public Company
- Specialties
- Pharmaceutical products and Vaccines
Locations
Employees at GSK
Updates
-
Glioblastoma (GBM) is the most common and aggressive cancerous brain tumour and is also one of the hardest to treat. Survival rates for GBM haven’t changed for decades, highlighting the need for new treatment options. On Glioblastoma Awareness Day, we reaffirm our dedication to researching and developing innovative treatments that could help those impacted by this challenging disease. #GBMDay
-
🚀 At GSK, R&D is central to our purpose: to get ahead of disease together. Much of our cutting-edge innovation happens in the UK, where we invested £1.5bn in 2024 alone. That’s why we welcome the UK Government’s new Life Sciences Sector Plan – particularly the reforms to incentivise more UK clinical trials, harness the power of health data and advance translational research. 🔗 Read the plan here: https://gsk.to/3TEi18t
-
-
Cryptococcal meningitis is a lesser-known but serious disease. It particularly impacts people living with HIV in lower-income countries and according to the World Health Organization, contributes to 15% of all HIV-related deaths globally. That's why, as part of a new project funded by Wellcome, our global health medicine unit will be collaborating on research with the University of Dundee and the University of Exeter to advance drug discovery for Cryptococcal meningitis and the fungal infection Candida auris, that is highly resistant to most available drug treatments. At GSK, we're committed to addressing this challenge through our global health R&D efforts. Our focus is on exploring innovative solutions for diseases like Cryptococcal meningitis due to its increasing resistance to current antifungals, and the disproportionate impact disease like this have on people living with HIV in lower income countries.
-
“I feel hopeless and frustrated” Many blood cancer patients face lifelong treatment challenges, but thankfully scientists are working hard to give them the quality of life they deserve. 🔗 Read about the experience for patients living with incurable blood cancers, and find out why they need more treatment options in our latest Behind the Science article: https://gsk.to/4lSST9T
-
-
Discover how our CEO, Emma Walmsley, champions team success through empowerment. In a new Linkedin News feature, Emma discusses how her definition of success has evolved throughout her career: "When leading a scale organisation, my professional success is about other people's success. Setting objectives and inspiring the team to exceed expectations." Watch the video to learn more, and share your thoughts on the topic below 👇
Has your definition of success evolved as your career progressed? For Emma Walmsley, CEO of GSK, it’s now all about empowering others. “ When you are leading a scale organization, the definition of my professional success is about other people's professional success,” says Walmsley. “ Really making sure that you are setting objectives and inspiring an organization to do more than they ever thought they could.” What does success mean to you? Share in the comments.
-
#News for #Investors and #Media: Data presented at #IAS2025 by ViiV Healthcare (our specialist HIV company) reinforce the importance of providing people living with #HIV with innovative treatment options that best suit their individual needs and preferences. 🔗 Find out more: https://gsk.to/4mcVP1x
-
#News for #Investors and #Media: ViiV Healthcare (our specialist HIV company) has expanded its voluntary license with the Medicines Patent Pool to include further innovative treatments alongside prevention to enable increased access and reach those most impacted by HIV. 🔗 Find out more: https://gsk.to/4eNrB2z
-
-
Our Africa Open Lab initiative aims to fund African-led research into high burden infectious diseases like malaria and tuberculosis (TB), bridging the research gap between Africa and the rest of the world. By supporting early-career scientists, offering technical assistance, and fostering knowledge exchange, Africa Open Labs aim to strengthen R&D capacity in Africa. Through partnering with leading African research and educational institutions the initiative also delivers training that focuses on the main skills gaps in early career researchers. Hear more from some of our funded researchers on what being a part of Africa Open Lab means to them, as we open a new call for proposals to find innovative new projects that could help find potential new solutions to high burden infectious diseases. 🔗 https://gsk.to/4lp9y5j
-
#News for #investors and #media: The United States Food and Drug Administration has accepted a regulatory application to expand the population indication for one of our vaccines. Access our website here. https://gsk.to/4lNhNYp